We thank Dr Aggarwal and colleagues for their interest in and valuable comments on two of our publications.1,2 Their first comment addressed the article on the high rates of conversion and reversion in monthly interferon-γ release assay (IGRA) results for health-care workers.1 They asked whether any participant with a positive IGRA subsequently developed active TB, which is an important issue. So far, none of the participants has developed active TB. We plan to screen participants for active TB at 1, 2, and 5 years. Their second comment addressed another article describing the change in IGRA results among participants taking medication to treat latent TB infection.2 They asked what is meant by negative conversion of the IGRA with treatment of latent TB infection. Unfortunately, the clinical meaning of such conversions is not clear, and long-term follow-up is required to answer the question.